Insider Stock Trading History of Mackay Martin


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Mackay Martin since year 2005. The trader's CIK number is 1414815. At the time of this reporting, Mackay Martin is the EVP & Global Head of R&D of Alexion Pharmaceuticals Inc . (stock ticker symbol ALXN). See this page for all insider trading activities at Alexion Pharmaceuticals Inc .


Stock purchases, sales, and option exercises reported by insider Mackay Martin since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-02-27 ALXN Alexion Pharmaceuticals Inc Sale 860 131.20 112,831
2017-02-28 ALXN Alexion Pharmaceuticals Inc Sale 625 131.70 82,312
2017-03-01 ALXN Alexion Pharmaceuticals Inc Sale 370 132.50 49,025
2017-02-09 ALXN Alexion Pharmaceuticals Inc Sale 217 126.84 27,524
2017-02-06 ALXN Alexion Pharmaceuticals Inc Sale 2,728 126.28 344,505
2016-05-16 ALXN Alexion Pharmaceuticals Inc Sale 4,097 139.81 572,801
2016-02-29 ALXN Alexion Pharmaceuticals Inc Sale 1,000 138.91 138,910
2016-02-08 ALXN Alexion Pharmaceuticals Inc Sale 1,966 139.17 273,608
2016-02-05 ALXN Alexion Pharmaceuticals Inc Sale 2,105 142.87 300,747
2015-08-03 ALXN Alexion Pharmaceuticals Inc Option Ex 43,500 140.83 6,126,105
2015-08-03 ALXN Alexion Pharmaceuticals Inc Sale 43,500 196.30 8,539,180
2015-05-14 ALXN Alexion Pharmaceuticals Inc Sale 4,056 160.33 650,298
2015-03-02 ALXN Alexion Pharmaceuticals Inc Sale 370 180.34 66,725
2015-02-10 ALXN Alexion Pharmaceuticals Inc Sale 3,897 174.03 678,194
2014-11-03 ALXN Alexion Pharmaceuticals Inc Option Ex 9,375 104.86 983,062
2014-11-03 ALXN Alexion Pharmaceuticals Inc Sale 9,375 191.52 1,795,500
2014-06-12 ALXN Alexion Pharmaceuticals Inc Sale 25,000 166.54 4,163,575
2014-06-12 ALXN Alexion Pharmaceuticals Inc Option Ex 25,000 104.86 2,621,500
2014-05-14 ALXN Alexion Pharmaceuticals Inc Sale 3,574 160.85 574,877

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mackay Martin (EVP & Global Head of R&D of Alexion Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.